MA-PERKINELMER
20.4.2020 15:02:08 CEST | Business Wire | Press release
PerkinElmer, Inc. , a global leader committed to innovating for a healthier world, today expanded its analysis and automation portfolio for quality, safety and content testing. Geared for pharmaceutical, semiconductor, biomonitoring, food, materials and academia labs, the new offerings will help streamline workflows, sharpen insights and performance and provide ease of use. They include:
NexION® 5000 Multi-Quadruple ICP-MS – for demanding trace element analyses, this solution drives accurate and repeatable results and helps future-proof labs. Leveraging new and proprietary technologies, it is the first in its category to offer four quadrupoles – meeting and exceeding rigorous trace-elemental testing requirements for labs working in areas like semiconductor R&D and device manufacturing as well as biomonitoring. The new offering goes beyond current triple-quad ICP-MS performance to deliver exceptionally low background equivalent concentrations (BECs) of <1 ppt even in hot plasma and outstanding detection limits in a matrix-tolerant, low-maintenance solution.
Spectrum™ 3 spectrometer – a tri-range FT-IR spectroscopy solution featuring 100 scans/second for pharmaceutical, polymer, materials, food, academic or chemical labs doing advanced research, product development or reaction monitoring. Working across solid, liquid or gas samples and including options for near, mid and far-IR ranges in one instrument, it brings strong flexibility. It is also suitable for users of varying skill levels as it is the first FT-IR platform to offer a fully integrated TG-IR hyphenation (EGA4000) solution.
For more advanced applications, the offering can be easily hyphenated with PerkinElmer’s TGA™ 8000 thermogravimetric analyzer and Clarus® SQ8 GC/MS chromatography system. Spectrum 3 also leverages PerkinElmer’s Spectrum™ 10 software (including integrated time resolved software and CFR 21 Part 11 compliance options) and cloud connectivity via NetPlus™ software – delivering accurate results, integrated workflows and global, real-time collaboration.
Spectrum™ Two + spectrometer - a powerful FT-IR solution for routine compositional and quality analyses that delivers fast and accurate results with secure, cloud-connectivity. It also offers a compact footprint, advanced UATR (universal attenuated total reflectance) accessory and rugged touchscreen.
S20 Autosamplers Series - brings sample automation speed, ruggedness and versatility to labs looking to boost their productivity and cost savings, as well as future-proof their spectroscopy capabilities.
“Whether lab professionals are working to ensure the efficacy of pharmaceuticals, meeting materials regulations, aiming for zero impurities in semiconductor processes, or testing for food adulteration, they want to be more productive and collaborative and create highly reliable results and fresh insights,” said Suneet Chadha, VP/GM, Applied Markets, PerkinElmer. “Our new four quadrupole ICP-MS, FT-IR and automation solutions are designed to empower scientists and technicians to look deeper, work smarter and prepare for future needs or requirements.”
About PerkinElmer
PerkinElmer enables scientists, researchers and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise at www.perkinelmer.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200420005047/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release
Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release
Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly
Fasset Hits $1B Valuation as SBI Group Leads $68M Series C to Scale AI-Powered Stablecoin Neobanking24.8.2026 08:03:00 CEST | Press release
Round led by SBI Group follows $51 million Series B raise in May 2026, marking ascent as one of the fastest-growing neobanking platforms. Capital will expand Own Network and deepen AI across stablecoin settlement, tokenization, and corridor banking. Fasset now processes more than $40 billion in annualized transaction volume, serving 3 million+ wallets and more than 1,000 enterprises across 125 countries. Fasset, the AI-powered stablecoin neobanking platform, today announced it has raised $68 million in Series C funding at a $1 billion valuation. The financing was led by SBI Group and follows Fasset’s $51 million Series B earlier this year, which brought Speedinvest onto the cap table alongside a group of strategic investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823503947/en/ Mohammad Raafi Hossain, Co-Founder and CEO, Fasset The new capital will support the expansion of Own Network, Fasset’s regulated financial
Zanders Expands DACH Region with New Office in Vienna, Austria24.8.2026 07:11:00 CEST | Press release
Zanders, the global treasury, risk, and technology consultancy, today announced a significant expansion of its DACH region with the opening of a new office in Vienna. The move builds on Zanders' continued growth across Germany, Austria, and Switzerland, and marks another step in the firm's strategy of deepening its presence in the markets where client demand for specialized treasury, risk, and corporate finance advisory is growing fastest. DACH has been one of Zanders' priority regions for several years, with the firm steadily expanding its team and client base across Germany and Switzerland. Austria represents a natural next step in that growth: in conversations with clients in the market, Zanders has seen growing interest in treasury transformation and financing support, as companies work through interest rate volatility, refinancing needs, and a broader shift toward more digitized, centralized treasury operations. The new Vienna office allows Zanders to be closer to clients' operati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom